Overview

Addition of Pyridostigmine to Conventional Management of Postdural Puncture Headache

Status:
Completed

Trial end date:
2024-01-03

Target enrollment:
0

Participant gender:
All

Summary

Postdural puncture headache (PDPH) is a major complication of neuraxial anesthesia that can occur following spinal anesthesia and with inadvertent Dural puncture during epidural anesthesia. The presence of Pyridostigmine in CSF would be expected to increase the level of acetylcholine in CSF and subsequently in the brain through inhibition of cholinesterase. The increased level of acetylcholine would produce cerebral vasoconstriction.

Phase:

Phase 4

Accepts Healthy Volunteers?

Accepts Healthy Volunteers

Details

Lead Sponsor:

Ain Shams University

Treatments:

Pyridostigmine Bromide

Criteria

Inclusion Criteria:

- Patients American Society of anesthesiologists' physical status (ASA) II because of
pregnancy.

- Patients diagnosed with Postdural puncture headache following intrathecal spinal
anesthesia for elective caesarean delivery.

Exclusion Criteria:

1. Patients with PDPH and a visual analog scale (VAS) score <5.

2. Patients with history of chronic headache, cluster headache, migraine, convulsions.

3. Patients with history of cerebrovascular accident, previous neurological diseases.

4. Patients with preeclampsia, eclampsia, coagulopathy.

5. Patients with severe bleeding (>20% of blood volume).

6. Patients undergoing treatment with vasopressors.

7. Patients with bronchial asthma.

8. Patients with arrhythmia, and any type of heart block.